Business Wire

  1. Charles River And CHDI Foundation Extend Multi-Decade Collaboration On Huntington's Disease Research 5/28/2025

    Charles River Laboratories International, Inc. and CHDI Foundation, Inc., today announced an extension of their ongoing drug discovery partnership into the foreseeable future.

  2. Nuclera And Cytiva Collaborate To Accelerate Characterization Of Proteins For Drug Development 5/28/2025

    Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery System, has announced a collaboration with Cytiva, a global life sciences leader.

  3. Global Summit On Microphysiological Systems Research Set To Shape The Future Of Drug Development And Disease Modeling 5/22/2025

    The 4th Annual MPS World Summit, hosted by the International MPS Society (IMPSS) and supported by EUROoCS, will take place in Brussels, Belgium this summer.

  4. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-1418, A Potential Best-In-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate 5/22/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-1418 (DB-1418), a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC).

  5. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-023 (ARTS-023), A Potential Best-In-Class, Novel CDK4 Selective Inhibitor 5/21/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-023 (formerly ARTS-023), a potential best-in-class, novel cyclin-dependent kinase 4 (CDK4) selective inhibitor.

  6. Pfizer Enters Into Exclusive Licensing Agreement With 3SBio 5/19/2025

    Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

  7. CytoTronics Expands Pixel Capability With Multi-Modal Cardiac Application For Early Screening Of Drug Candidates In Cardiovascular Research 5/13/2025

    CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched their novel Cardiac application today—the next key offering in its Pixel application portfolio.

  8. Lantern Pharma Secures FDA Clearance For Planned Phase 1b/2 Trial Of LP-184 In Biomarker-Defined, Treatment-Resistant NSCLC Patients With High Unmet Clinical Need 5/12/2025

    Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC) where there is a need to improve patient outcomes.

  9. Intrepid Labs Launches To Transform Drug Formulation With AI And Autonomous Labs 5/12/2025

    Intrepid Labs, a biotechnology company transforming drug formulation development through the use of artificial intelligence (AI) and robotics, emerged from stealth today to accelerate therapeutics development through effective formulations that improve clinical performance.

  10. Cadence Unveils Millennium M2000 Supercomputer With NVIDIA Blackwell Systems To Transform AI-Driven Silicon, Systems And Drug Design 5/7/2025

    At its annual flagship user event, CadenceLIVE Silicon Valley 2025, Cadence today announced a major expansion of its Cadence Millennium Enterprise Platform with the introduction of the new Millennium M2000 Supercomputer featuring NVIDIA Blackwell systems, which delivers AI-accelerated simulation at unprecedented speed and scale across engineering and drug design workloads.